ATE419277T1 - Faktor-ixa-spezifische antikörper, die faktor- viiia-ähnliche wirkung zeigen - Google Patents
Faktor-ixa-spezifische antikörper, die faktor- viiia-ähnliche wirkung zeigenInfo
- Publication number
- ATE419277T1 ATE419277T1 AT04764918T AT04764918T ATE419277T1 AT E419277 T1 ATE419277 T1 AT E419277T1 AT 04764918 T AT04764918 T AT 04764918T AT 04764918 T AT04764918 T AT 04764918T AT E419277 T1 ATE419277 T1 AT E419277T1
- Authority
- AT
- Austria
- Prior art keywords
- factor
- effects
- specific antibodies
- ligands
- exhibit
- Prior art date
Links
- 239000003446 ligand Substances 0.000 abstract 4
- 108010048049 Factor IXa Proteins 0.000 abstract 3
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 1
- 108010076282 Factor IX Proteins 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 229960004222 factor ix Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002947 procoagulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/661,366 US7297336B2 (en) | 2003-09-12 | 2003-09-12 | Factor IXa specific antibodies displaying factor VIIIa like activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE419277T1 true ATE419277T1 (de) | 2009-01-15 |
Family
ID=34273861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04764918T ATE419277T1 (de) | 2003-09-12 | 2004-09-07 | Faktor-ixa-spezifische antikörper, die faktor- viiia-ähnliche wirkung zeigen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7297336B2 (de) |
| EP (1) | EP1660536B1 (de) |
| JP (1) | JP4887148B2 (de) |
| AT (1) | ATE419277T1 (de) |
| AU (1) | AU2004271706B2 (de) |
| CA (1) | CA2538895A1 (de) |
| DE (1) | DE602004018788D1 (de) |
| ES (1) | ES2320665T3 (de) |
| WO (1) | WO2005025615A2 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT411997B (de) * | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| ES2592271T3 (es) | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos |
| EP1760092A1 (de) * | 2005-08-26 | 2007-03-07 | Applied Research Systems ARS Holding N.V. | System für Screening von Zellen mit hoher Expression von einem interessierenden Protein |
| EP4218801A3 (de) | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antikörpermodifizierungsverfahren zur reinigung eines bispezifischen antikörpers |
| EP4342995A3 (de) | 2006-03-31 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur kontrolle der blut-pharmazeutizität von antikörpern |
| WO2009041643A1 (ja) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
| PT2644698T (pt) | 2010-11-17 | 2018-01-31 | Chugai Pharmaceutical Co Ltd | Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue |
| EP2902787B1 (de) * | 2012-09-28 | 2018-03-28 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur beurteilung der blutgerinnungsreaktion |
| AU2014325063B2 (en) | 2013-09-27 | 2019-10-31 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
| WO2015138600A2 (en) * | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定ｆｖｉｉｉ的反應性之方法 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| EP3398965A4 (de) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur förderung der effizienz der reinigung von polypeptid mit fc-region |
| SG11201809642TA (en) * | 2016-05-16 | 2018-11-29 | Baxalta Inc | Anti-factor ix padua antibodies |
| SG11201901961SA (en) | 2016-09-06 | 2019-04-29 | Chugai Pharmaceutical Co Ltd | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
| CN110023339A (zh) * | 2016-09-23 | 2019-07-16 | Csl有限公司 | 凝血因子结合蛋白及其应用 |
| WO2018098363A2 (en) * | 2016-11-23 | 2018-05-31 | Bioverativ Therapeutics Inc. | Bispecific antibodies binding to coagulation factor ix and coagulation factor x |
| EP3848396A1 (de) | 2017-02-01 | 2021-07-14 | Novo Nordisk A/S | Antikörper gegen faktor ix und faktor x zur förderung der blutgerinnung |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| MA50667A (fr) | 2017-09-29 | 2020-08-05 | Chugai Pharmaceutical Co Ltd | Molécule multispécifique de liaison à l'antigène ayant une activité de substitution de la fonction de cofacteur du facteur viii de coagulation sanguine (fviii), et formulation pharmaceutique contenant ladite molécule en tant que principe actif |
| US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
| EP3830135A1 (de) * | 2018-08-01 | 2021-06-09 | Novo Nordisk A/S | Verbesserte prokoagulatorische antikörper |
| CA3123177A1 (en) * | 2018-12-21 | 2020-06-25 | Kymab Limited | Fixaxfx bispecific antibody with common light chain |
| CN115052898A (zh) | 2020-01-30 | 2022-09-13 | 诺和诺德股份有限公司 | 双特异性因子viii模拟抗体 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT368883B (de) | 1980-07-22 | 1982-11-25 | Immuno Ag | Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| AU678987B2 (en) | 1992-08-27 | 1997-06-19 | Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis | Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein |
| DK128093D0 (da) | 1993-11-12 | 1993-11-12 | Novo Nordisk As | Hidtil ukendte forbindelser |
| MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
| WO1999001476A1 (en) | 1997-07-03 | 1999-01-14 | Smithkline Beecham Corporation | CRYSTAL STRUCTURES OF ANTI-FACTOR IX Fab FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN |
| AT411997B (de) * | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| CU23007A1 (es) * | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| RU2306320C9 (ru) * | 2001-05-03 | 2008-01-27 | Мерк Патент Гмбх | Рекомбинантное опухолеспецифичное антитело (варианты) и его применение |
-
2003
- 2003-09-12 US US10/661,366 patent/US7297336B2/en active Active
-
2004
- 2004-09-07 JP JP2006525744A patent/JP4887148B2/ja not_active Expired - Fee Related
- 2004-09-07 WO PCT/EP2004/009975 patent/WO2005025615A2/en active Application Filing
- 2004-09-07 ES ES04764918T patent/ES2320665T3/es active Active
- 2004-09-07 AU AU2004271706A patent/AU2004271706B2/en active Active
- 2004-09-07 CA CA002538895A patent/CA2538895A1/en not_active Abandoned
- 2004-09-07 AT AT04764918T patent/ATE419277T1/de active
- 2004-09-07 EP EP04764918A patent/EP1660536B1/de active Active
- 2004-09-07 DE DE602004018788T patent/DE602004018788D1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US7297336B2 (en) | 2007-11-20 |
| JP2007504812A (ja) | 2007-03-08 |
| CA2538895A1 (en) | 2005-03-24 |
| JP4887148B2 (ja) | 2012-02-29 |
| EP1660536B1 (de) | 2008-12-31 |
| WO2005025615A3 (en) | 2005-06-02 |
| EP1660536A2 (de) | 2006-05-31 |
| AU2004271706A1 (en) | 2005-03-24 |
| ES2320665T3 (es) | 2009-05-27 |
| DE602004018788D1 (de) | 2009-02-12 |
| AU2004271706B2 (en) | 2010-09-02 |
| US20050058640A1 (en) | 2005-03-17 |
| WO2005025615A2 (en) | 2005-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE419277T1 (de) | Faktor-ixa-spezifische antikörper, die faktor- viiia-ähnliche wirkung zeigen | |
| ATE405650T1 (de) | Produktion von ganzen antikörpern in prokaryontischen zellen | |
| BRPI0418251C1 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
| SE0301700D0 (sv) | Novel compounds | |
| CY1116728T1 (el) | Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων | |
| EA200700225A1 (ru) | Аналоги тетрапептида | |
| DE60313597D1 (de) | Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis | |
| SE0200920D0 (sv) | Novel compounds | |
| UA108193C2 (uk) | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| EA200601554A1 (ru) | Замещенные индол-о-глюкозиды | |
| WO2007076085A3 (en) | Fused pyrimidones and thiopyrimidones, and uses thereof | |
| DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
| EA200700175A1 (ru) | Композиции и способы лечения воспалительных заболеваний | |
| JO2373B1 (en) | W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors | |
| HUP0302384A2 (hu) | Sejtek bioenergia metabolizmusában szerepet játszó biokémiai vegyületeket tartalmazó készítmények és alkalmazásuk | |
| IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
| DE50310516D1 (de) | Fredericamycin-derivate | |
| EA201892184A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора | |
| DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| CY1113116T1 (el) | Υποκατεστημενες 4-αμινοκυκλοεξανολες | |
| SE0302139D0 (sv) | Novel compounds | |
| ATE308331T1 (de) | Kombinationspräparat enthaltend monozyten- abgeleitete zellen zur behandlung von neoplastischen oder infektiösen erkrankungen | |
| EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
| EA200401319A1 (ru) | Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине | |
| EA200870058A1 (ru) | Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1660536 Country of ref document: EP |